“The present circumstance has uncovered some structural weaknesses within the EU’s medicines offer chain in addition to a higher dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides said. She proposed that offer chain problems be addressed within an EU pharmaceutical method expected for being introdu